Mihran Yenikomshian
Education
M.B.A., F.W. Olin Graduate School of Business, Babson College; B.A., quantitative economics and computer science, Tufts University
Summary of Experience
Mr. Yenikomshian specializes in software and technology assessment and testing, AI, algorithms, source-code analysis, data analysis, and economic modeling. He has prepared technical expert reports and provided deposition, trial, and arbitration testimony in matters concerning software functionality, algorithmic decision making, intellectual property, big tech, and digital privacy. Mr. Yenikomshian’s work involves examining source code and technical documentation, testing how applications operate, tracing data flows including Large Language Model (LLM) training data, and communicating complex technical findings to courts, arbitrators, and non-technical audiences. In recent algorithm-focused litigation, he served as a source code expert in algorithmic pricing matters. In Thomson Reuters v. ROSS Intelligence, a case involving an AI-powered legal research platform, he submitted a rebuttal expert report and was deposed regarding potential damages associated with alleged tying of Westlaw products. Mr. Yenikomshian has also testified in confidential mass arbitrations addressing website collection and transmission of browsing data to third-party analytics and advertising services, including how data flows vary with user settings. Previously, he testified on behalf of the US Department of Justice in US v. Jitesh Thakkar, explaining source code in court to assess whether trading software implemented specified functionality. His broader experience includes source-code reviews in copyright and trade-secret disputes, development of interactive decision-support software, and publications on machine learning and code review in litigation. Mr. Yenikomshian is a member of the American Bar Association, where he has previously held leadership roles on committees addressing biotechnology, big data, data science, and AI. Before joining Analysis Group, he was a partner in a software development and staffing technology firm.
- Chasom Brown, et al. v. Google LLC
- Facebook Inc. Derivative Litigation
- Patrick Calhoun, et al. v. Google LLC
- Pharmaceutical Off-Label Promotion & Kickbacks Settlements
- Retrospective Study of Medication Adherence Among Adults with Metastatic Colorectal Cancer
- United States of America et al ex rel Brown v Celgene Corp
-
Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study
Leukemia Research, 2025
2025Andritsos LA, McBride A, Tang D, Barghout V, Zanardo E, Song R, Huynh L, Yenikomshian M, Makinde AY, Hughes C, Hanna KS, Patel K
-
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study
Journal of Medical Economics, 2025
2025Ball BJ, Song R, Zanardo E, Huynh L, Mohan M, Pinaire M, Tang D, Yenikomshian M, Swanson A, Gavrilov S, Slaff S
-
Real-World Treatment Patterns of Patients with Basal Cell Carcinoma Using Sonidegib and Vismodegib: Discontinuation Rates and Clinical Conditions During Treatment
Dermatology and Therapy, 2025
2025Lebwohl MG, Rigel DS, Eroglu Z, Barghout VE, Gupta D, Zanardo E, Huynh L, Yenikomshian MA, Squittieri N, Ferro TJ, Patel K
-
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
BMC Ophthalmology, 2023
2023Karpecki P, Barghout V, Schenkel B, Huynh L, Khanal A, Mitchell B, Yenikomshian M, Zanardo E, Matossian C
-
Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis
Advances in Therapy, 2023
2023Cheng WY, Fishman J, Yenikomshian M, Mahendran M, Kunzweiler C, Vu JD, Duh MS
-
Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting
Scientific Reports, 2023
2023Hamy V, Llop C, Yee CW, Garcia-Gancedo L, Maxwell A, Chen WH, Tomlinson R, Bobbili P, Bendelac J, Landry J, DerSarkissian M, Yenikomshian M, Mody EA, Duh MS, Williams R
-
Mitigating Antitrust Concerns when Competitors Share Data Using Blockchain Technology
Harvard Journal of Law & Technology, Volume 34, Digest Spring 2021
2021Arcelus A, Nocera N, Yenikomshian M
-
Health Cos. Can Reduce FCA Risk by Leveraging Data
Law360, 2021
2021Jenny B, Yenikomshian M, Greenberg PE
-
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
The Oncologist, 2021
2021Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS
-
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
Advances in Therapy, 2021
2021Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS
-
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Oncologist, 2020
2020Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F, Duh MS
-
Modeling the potential impact of abuse-deterrent opioids on medical resource utilization
Journal of Medical Economics, 2019
2019Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL
-
Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review
Current Medical Research and Opinion, 2019
2019Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M
-
Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib
Clinical Colorectal Cancer. 2018 Sep;17(3):e531-e539
2018Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS
-
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients
Journal of Opioid Management. Sep/Oct 2017;13(5):291-301
2017Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL
-
-
A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids
Journal of Pain, 2016
2016White A, Yenikomshian M, Carson M, Masters E, Roland C
-
The epidemiology of herpes zoster and its complications in Medicare cancer patients
BMC Infect Dis. 2015 Feb 27;15(1):106. doi: 10.1186/s12879-015-0810-6
2015Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS
-
The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk
J Med Econ. 2015 Apr 1:1-9. [Epub ahead of print]
2015Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG
-
June 6, 2024
-
August 29, 2026
-
March 24, 2026
-
December 19, 2025
-
October 7, 2025
-
March 10, 2025
-
January 3, 2025
-
April 9, 2024
-
December 1, 2023
-
March 2, 2023